The FDA is warning of a potential seizure risk associated with e-cigarettes, especially among asolescents and young adults; Sorrento Therapeutics is suing its business partner, alleging he purchased and then tried to prevent the release of their cancer drug; states are suing the Trump administration over plans to loosen school lunch nutrition standards.
The FDA has issued a statement warning of potential seizure risk associated with e-cigarette use. According to the FDA, there have been reports indicating that some people who use e-cigarettes, particularly adolescents and young adults, are experiencing seizures following their use. Since 2010, there have been 35 reported cases, and the reports have lacked enough information to determine a specific brand or sub-brand of e-cigarette. The agency noted that it is not yet clear if there is a direct relationship between the use of e-cigarettes and risk of seizures. Sorrento Therapeutics is suing Patrick Soon-Shiong, MBBCh, MSS, FRCS, alleging that the biotech entrepreneur purchased and then tried to prevent the launch of Sorrento’s experimental cancer drug that would have competed with his blockbuster drug, Abraxane. According to the Los Angeles Times, the legal dispute dates back to 2014 when Sorrento’s drug, Cynviloq, was expected to be approved by the FDA. Soon-Shiong has denied the allegations and said the suits are without merit.Six states and Washington, DC, are suing the Trump administration for plans to roll back the nutrition standards of school lunches implemented by the Obama administration, reported the The Wall Street Journal. The lawsuit is the first to challenge the administration’s plans to loosen the standards, which require carbohydrate-rich foods be made with whole grains with a sodium limit of 640 milligrams. Under the new plan, school lunches would be required to serve whole grains in half of lunch menu items with a sodium limit of 1230 miligrams.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More